Skip to main content

Table 2 Baseline characteristics of subjects treated with either rituximab or cyclophosphamide and stratified by primary endpoint outcome

From: Reanalysis of the Rituximab in ANCA-Associated Vasculitis trial identifies granulocyte subsets as a novel early marker of successful treatment

  Rituximab p Value Cyclophosphamide p Value
  Success, n = 60 Failure, n = 34   Success, n = 48 Failure, n = 45  
Age 53.25 56 0.44 51.3 51.9 0.85
Sex    0.52    0.68
Male 45 % 53 %   50 % 56 %  
Female 55 % 47 %   50 % 44 %  
ANCA-associated vasculitis type    0.66    0.27
PR3 67 % 62 %   60 % 66 %  
MPO 33 % 38 %   40 % 34 %  
Newly diagnosed at enrollment 48 % 50 % 1.0 56 % 36 % 0.06
BVAS/WG 7.97 ± 0.36 8.09 ± 0.52 0.85 8.42 ± 0.53 7.60 ± 0.47 0.25
  1. ANCA anti-neutrophil cytoplasmic antibodies, BVAS-WG Birmingham Vasculitis Activity Score for Wegener’s granulomatosis, MPO myeloperoxidase, PR3 proteinase 3